Skip to content

Author

C. Hengstenberg

We have 12 of 900 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Modulating atherosclerotic plaque formation by targeting plasminogen receptor PlgRKT

Macrophages are essential for atherosclerotic plaque progression. Recently a plasminogen receptor, Plg-RKT was shown to modulate monocyte and macrophage migration and lipid metabolism. However, its function on atherosclerotic development is not described yet. The aim of this study was to define the effect...

J. Kral-Pointner, L. Boccuni, M. Mussbacher et al. · 0 citations
Open access Oct 2026

FH genotype stratifies LDL-C–lowering response and improves diagnostic discrimination in severe hypercholesterolemia

Severe hypercholesterolemia encompasses a broad range of phenotypes and treatment responses. Whether lipid-lowering therapy (LLT) effectiveness differs in patients with versus without pathogenic heterozygous familial hypercholesterolemia (FH) variants is not well defined, and it is uncertain if response patterns...

J. Bernhard, L. Galli, I. Undt et al. · 0 citations
Open access Oct 2026

Association of LDL-C/ApoB ratio with pathogenic variants in familial hypercholesterolemia

Familial hypercholesterolemia (FH) is an inherited disorder of lipoprotein metabolism marked by elevated low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease (ASCVD). Conventional diagnostic tools such as the Dutch Lipid Clinic Network (DLCN) score do not assess qualita...

J. Bernhard, F. Wollmann, L. Galli et al. · 0 citations
Open access Oct 2026

Recurrence of transthyretin amyloid cardiomyopathy following heart transplantation - a long term follow-up analysis

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease of the myocardium. Despite advances in disease-modifying therapeutics, heart transplantation (HTX) remains an established treatment option of last resort in selected patients. In this retrospective multi-centre analysis, ATTR-CM patien...

M. Poledniczek, M. Ungericht, P. Schlegel et al. · 0 citations
Open access Oct 2026

Prognostic associations of major bleeding in anticoagulated patients with atrial fibrillation after TAVI: a post hoc analysis of the ENVISAGE-TAVI AF trial

Major bleeding (MB) is a serious complication in anticoagulated patients with atrial fibrillation (AF) after transcatheter aortic valve implantation (TAVI). The prognostic implications of bleeding occurrence and anatomical location in this high-risk population remain insufficiently characterised. To invest...

G. Dangas, J. Nicolas, C. Hengstenberg et al. · 0 citations
Nov 2026

Efficacy and Safety of Routine Postdilation in Balloon-Expandable Transcatheter Aortic Valve Implantation Platform: The DUOTAP Randomized Clinical Trial.

Importance In patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI), asymmetric valve expansion can estimate prosthetic dysfunction and death. Postdilation has shown promising results in optimizing valve geometry in observational studies; however, randomized evidence is cur...

M. Autherith, K. Singer, L. Hauptmann et al. · 1 citation
Open access Oct 2026

[68Ga]Ga-FAPI PET to detect early myocardial fibrotic activity in patients with severe aortic stenosis undergoing TAVR

Aortic stenosis (AS) causes ongoing pressure overload on the left ventricle and leads to progressive myocardial remodeling. Early diffuse interstitial fibrosis often remains difficult to detect with conventional imaging techniques. Fibroblast activation protein (FAP)–targeted positron emission tomography (PET) ca...

K. Hamzaraj, A. Lazarević, R. Sciagra et al. · 0 citations
Open access Oct 2026

NT-proBNP and UACR for outcome prediction in HFrEF

NTproBNP is the central biomarker for risk stratification in heart failure with reduced ejection fraction (HFrEF). The urinary albumin-to-creatinine ratio (UACR) reflects renal and microvascular injury, but its independent and incremental prognostic value beyond NTproBNP remains uncertain. To evaluate the...

N. Panagiotides, S. Prausmueller, H. Arfsten et al. · 0 citations
Oct 2026

Definition and Prognosis of Mitral Regurgitation in Transthyretin Amyloid Cardiomyopathy: A Multicenter International Cohort Study.

BACKGROUND In transthyretin amyloid cardiomyopathy, mitral regurgitation (MR) severity may be underestimated by conventional (semi-)quantitative echocardiographic criteria due to restrictive low-flow hemodynamics. We sought to define and validate disease-specific MR risk thresholds and compare their prognostic performa...

L. Hauptmann, C. Kronberger, S. Schwarting et al. · 0 citations
Open access Aug 2026

One-Year Outcomes of M-TEER With the PASCAL System in Atrial and Ventricular FMR: Insights From the MiCLASP Postmarket Clinical Follow-Up Study.

One-year MiCLASP results support the safety of mitral transcatheter edge-to-edge repair with the PASCAL system in both AFMR and VFMR, with comparable echocardiographic, functional, and quality-of-life changes, despite baseline differences in clinical presentation.

A. Mahabadi, T. Rassaf, T. Kister et al. · 0 citations
Aug 2026

Predictive value of echocardiography in assessment of all-cause death in cardio-oncologic patients: a single-center prospective registry

The authors' prospective registry involving unselected cancer patients with high incidence of metastases revealed high mortality in patients with suspected cardiotoxicity, with a relatively low incidence of 9.8% cardiovascular death.

V. Kokabi, A. Spannbauer, H. Erdogan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.